- Home
- CNF vs LTRN Comparison
CNF vs LTRN Comparison
Compare CNF & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- LTRN
- Stock Information
- Founded
- CNF 1999
- LTRN 2013
- Country
- CNF China
- LTRN United States
- Employees
- CNF 691
- LTRN N/A
- Industry
- CNF Finance: Consumer Services
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- LTRN Health Care
- Exchange
- CNF Nasdaq
- LTRN Nasdaq
- Market Cap
- CNF 35.7M
- LTRN 36.0M
- IPO Year
- CNF 2018
- LTRN 2020
- Fundamental
- Price
- CNF $0.66
- LTRN $3.12
- Analyst Decision
- CNF
- LTRN Strong Buy
- Analyst Count
- CNF 0
- LTRN 1
- Target Price
- CNF N/A
- LTRN $25.00
- AVG Volume (30 Days)
- CNF 301.2K
- LTRN 50.9K
- Earning Date
- CNF 04-30-2025
- LTRN 08-07-2025
- Dividend Yield
- CNF N/A
- LTRN N/A
- EPS Growth
- CNF N/A
- LTRN N/A
- EPS
- CNF 0.08
- LTRN N/A
- Revenue
- CNF $85,661,735.00
- LTRN N/A
- Revenue This Year
- CNF $252.34
- LTRN N/A
- Revenue Next Year
- CNF N/A
- LTRN N/A
- P/E Ratio
- CNF $8.31
- LTRN N/A
- Revenue Growth
- CNF N/A
- LTRN N/A
- 52 Week Low
- CNF $0.37
- LTRN $2.55
- 52 Week High
- CNF $2.84
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- CNF 61.10
- LTRN 43.98
- Support Level
- CNF $0.42
- LTRN $3.05
- Resistance Level
- CNF $0.66
- LTRN $3.24
- Average True Range (ATR)
- CNF 0.08
- LTRN 0.17
- MACD
- CNF 0.02
- LTRN 0.01
- Stochastic Oscillator
- CNF 64.71
- LTRN 15.64
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.